NexImmune, Inc.

Biopharmaceutical company with a mission to help cure cancer by directing T cell function using precision technology and personalized therapeutics.

The Company’s proprietary AIM Technology uses artificial Antigen Presenting Cells (aAPC) to create highly targeted T cell-based immunotherapies. In preclinical studies, aAPC have demonstrated the ability to clear established tumors by expanding antigen-specific T cells when injected directly (in vivo) or when used as part of an ex vivo cellular expansion system. 

January 18, 2021 in NexImmune, Inc., Portfolio

Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officer

With more than 25 years of clinical development leadership experience at companies such as Celgene and Kite Pharmaceuticals, Dr. Knight will now lead the clinical development of NexImmune’s novel immunotherapy…
Read More
January 4, 2021 in NexImmune, Inc., Portfolio

NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor

NexImmune Inc. Zeldis formerly served as Celgene CMO and CEO of Celgene Global Health Weber is a renowned melanoma specialist and leading immunotherapy translational and clinical scientist Both will help…
Read More
December 7, 2020 in NexImmune, Inc., Portfolio

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic hematopoietic cell transplantation (allo-HSCT) GAITHERSBURG, Md., Dec.…
Read More
December 16, 2019 in NexImmune, Inc., Portfolio

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

NexImmune Inc. NexImmune Appoints Sol Barer as Chairman of the Board of Directors December 16, 2019
Read More
October 30, 2019 in NexImmune, Inc., Portfolio

NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome

NexImmune Inc. NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome ND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients…
Read More
December 11, 2018 in NexImmune, Inc., Portfolio

NexImmune Granted Key US Patent for Core E+E Technology

GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the United States Patent and Trademark Office has issued…
Read More
January 2, 2018 in NexImmune, Inc., Portfolio

Celgene vet Barer lines up a $23M startup round for next-gen I/O tech out of Johns Hopkins

After spending the past year in the hot seat as chairman at a badly dysfunctional Teva, Celgene co-funder Sol Barer can get back to the business of ramping up biotech…
Read More